Literature DB >> 26763765

Blood Transfusion in Major Abdominal Surgery for Malignant Tumors: A Trend Analysis Using the National Surgical Quality Improvement Program.

Brett L Ecker1, Kristina D Simmons1, Salman Zaheer1, Sarah-Lucy C Poe1, Edmund K Bartlett1, Jeffrey A Drebin1, Douglas L Fraker1, Rachel R Kelz1, Robert E Roses1, Giorgos C Karakousis1.   

Abstract

IMPORTANCE: Blood transfusion can be a lifesaving treatment for the surgical patient, yet transfusion-related immunomodulation may underlie the association of allogeneic transfusion with increased perioperative morbidity and possibly poorer long-term oncologic outcomes.
OBJECTIVE: To evaluate trends in transfusion rates for major abdominal oncologic resections to assess changes in recent clinical practice (given the accumulating evidence of the deleterious effects of blood transfusion). DESIGN, SETTING, AND PARTICIPANTS: Retrospective review of a population-based registry of all hospitals participating in the American College of Surgeons National Surgical Quality Improvement Project (2005-2013 Participant Use Data Files), which was queried for patients who underwent major resection of a pancreatic, hepatic, or gastric malignant tumor. Data analysis was performed from July to August 2015. MAIN OUTCOME AND MEASURES: The primary outcome was the transfusion of any quantity of packed red blood cells. Transfusion rates were calculated for the perioperative period, which was defined as the time from the start of surgery to 72 hours after surgery. Secondary outcomes included wound infection, myocardial infarction, and renal insufficiency, and the rates of these complications were calculated as well. Trend analysis was performed for each year of data to evaluate for changes over the study period.
RESULTS: A total of 19 680 patients (median age, 65.0 years [interquartile range, 57.0-73.0 years]) were identified, of whom 5900 (30.0%) received a blood transfusion (of 13 657 patients who underwent a pancreatic resection, 4074 required transfusion [29.8%]; of 1605 patients who underwent a gastric resection, 378 required transfusion [23.6%]; and of 4418 patients who underwent a hepatic resection, 1448 required transfusion [32.8%]). There was a significant trend toward decreasing rates of transfusion during the study period (z = -7.89, P < .001), which corresponded to an absolute 6.1% decrease in the rate of transfusion of packed red blood cells from 2005 to 2013 (ie, from 32.8% to 26.7%). There was no significant change in the rates of postoperative wound infection or renal insufficiency during this time period, but there was an increased rate of perioperative myocardial infarction during the study period (0.33% absolute increase; z = 3.15, P = .002). CONCLUSIONS AND RELEVANCE: Over 9 years of contemporary practice, a trend of less perioperative blood transfusions for oncologic abdominal surgery was observed. Further studies are needed to assess whether these trends reflect changes in operative techniques, hospital cohorts, or transfusion thresholds.

Entities:  

Mesh:

Year:  2016        PMID: 26763765     DOI: 10.1001/jamasurg.2015.5094

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  12 in total

1.  Blood transfusion and postoperative complications: a cautionary comment.

Authors:  Jian-Hong Zhong; Bang-De Xiang; Le-Qun Li
Journal:  Transl Gastroenterol Hepatol       Date:  2016-07-18

2.  Declining Use of Red Blood Cell Transfusions for Gastrointestinal Cancer Surgery: A Population-Based Analysis.

Authors:  Jesse Zuckerman; Natalie Coburn; Jeannie Callum; Alyson L Mahar; Victoria Zuk; Yulia Lin; Robin McLeod; Alexis F Turgeon; Haoyu Zhao; Emily Pearsall; Guillaume Martel; Julie Hallet
Journal:  Ann Surg Oncol       Date:  2020-11-09       Impact factor: 5.344

3.  Comprehensive analysis of in-hospital delirium after major surgical oncology procedures: A population-based study.

Authors:  Marco Bandini; Michele Marchioni; Felix Preisser; Sebastiano Nazzani; Zhe Tian; Markus Graefen; Francesco Montorsi; Fred Saad; Shahrokh F Shariat; Luigi Schips; Alberto Briganti; Pierre I Karakiewicz
Journal:  Can Urol Assoc J       Date:  2019-09-27       Impact factor: 1.862

4.  Efficiency of Blood Utilization in Elective Oncosurgeries in a Tertiary Care Cancer Centre: A Case for Data Disaggregation.

Authors:  Shalini Bajpai; Aveek Jayant
Journal:  Indian J Surg Oncol       Date:  2022-01-25

5.  Postoperative patient blood management: transfusion appropriateness in cancer patients.

Authors:  Lucia Merolle; Chiara Marraccini; Erminia Di Bartolomeo; Maria T Montella; Thelma A Pertinhez; Roberto Baricchi; Alessandro Bonini
Journal:  Blood Transfus       Date:  2020-07-22       Impact factor: 3.443

6.  Impact of peri-operative blood transfusion on post-operative infections after radical gastrectomy for gastric cancer: a propensity score matching analysis focusing on the timing, amount of transfusion and role of leukocyte depletion.

Authors:  Hua Xiao; Hu Quan; Shuguang Pan; Bin Yin; Wei Luo; Gang Huang; Yongzhong Ouyang
Journal:  J Cancer Res Clin Oncol       Date:  2018-03-23       Impact factor: 4.553

7.  Peri-Operative Blood Transfusion Does Not Influence Overall and Disease-Free Survival After Radical Gastrectomy for Stage II/III Gastric Cancer: a Propensity Score Matching Analysis.

Authors:  Hua Xiao; Wu Liu; Hu Quan; Yongzhong Ouyang
Journal:  J Gastrointest Surg       Date:  2018-05-18       Impact factor: 3.452

8.  Patient Blood Management improves outcome in oncologic surgery.

Authors:  Vivienne Keding; Kai Zacharowski; Wolf O Bechstein; Patrick Meybohm; Andreas A Schnitzbauer
Journal:  World J Surg Oncol       Date:  2018-08-07       Impact factor: 2.754

9.  Best achievable results need territorial familiarity: Impact of living donor liver transplant experience on outcomes after pancreaticodoudenectomy.

Authors:  Abu Bakar H Bhatti; Roshni Z Jafri; Nasir A Khan
Journal:  Ann Med Surg (Lond)       Date:  2020-05-30

10.  Prediction of perioperative transfusions using an artificial neural network.

Authors:  Steven Walczak; Vic Velanovich
Journal:  PLoS One       Date:  2020-02-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.